Clinical Transfers®: State-of-the-Art Management for NSCLC: Novel Targets and Therapies

Program Overview

The landscape of precision medicine for non-small cell lung cancer (NSCLC) is continually evolving with an ever-expanding armamentarium of targeted agents. This educational activity is designed to provide a synopsis of novel targets and therapies. Jacob Sands, MD, a thoracic medical oncologist, will provide the latest data for newly approved and investigational MET and RET inhibitors, as well as the latest evidence for drug-antibody conjugates directed towards HER2, HER3, TROP2, and B7-H3.

Credit Expired

Target Audience

This activity is designed to meet the educational needs of oncology and pathology clinicians involved in the treatment of patients with non-small cell lung cancer (NSCLC).

Educational Objectives

Upon completion of this activity, participants should be better able to:

Assess the potential role of novel therapies directed against TROP2 and other emerging targets in the management of non-small cell lung cancer (NSCLC)
Identify the potential impact of HER2-/3-directed therapies on the current NSCLC treatment algorithm

Activity Faculty

Jacob Sands, MD

Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA

Featured RMEI CE Activities – Earn CE Credit(s)

Clinical Transfers®: State-of-the-Art Management for NSCLC: Novel Targets and Therapies

Program Overview

Target Audience

Educational Objectives

Activity Faculty

Jacob Sands, MD

Advances in Precision Medicine for Relapsed/Refractory Diffuse Large B-Cell Lymphoma Care: A Care Team Forum®

Refining Management of CMV After Transplant: Exploiting Recent Advances to Alleviate Patient Burden

Overcoming Obstacles to Optimal Multiple Sclerosis (MS) Care in Minority Patient Populations

Subscribe